![Helen Thackray](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Helen Thackray
Corporate Officer/Principal bij
Holy Cross Hospital (Maryland)
Vermogen: 1 M $ op 31-05-2026
Profiel
Helen M.
Thackray is currently a Member of the Institutional Review Board at Holy Cross Hospital (Maryland) and an Assistant Clinical Professor at GW School of Medicine & Health Sciences since 2000.
Former positions include Independent Director at ImmunoGen, Inc. from 2021 to 2024, Chief Research & Development Officer at BioCryst Pharmaceuticals, Inc. from 2021 to 2025, Vice President-Clinical Product Development at Biosynexus, Inc. from 2001 to 2006, Chief Medical Officer & SVP-Clinical Development at GlycoMimetics, Inc. from 2012 to 2021, and Member of the Institutional Review Board at the National Center for Health Statistics.
Education includes undergraduate studies at Stanford University and a doctorate from GW School of Medicine & Health Sciences.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 13-04-2026 | 161.618 ( 0,06% ) | 1 M $ | 31-05-2026 |
Actieve functies van Helen Thackray
| Bedrijven | Functie | Begin |
|---|---|---|
Holy Cross Hospital (Maryland) | Corporate Officer/Principal | - |
Gw School of Medicine & Health Sciences
 Gw School of Medicine & Health Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01-01-2000 |
Eerdere bekende functies van Helen Thackray
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-09-2025 |
| IMMUNOGEN, INC. | Directeur/Bestuurslid | 12-02-2024 |
GlycoMimetics, Inc.
 GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Hoofd Techniek/Wetenschap/O&O | 19-03-2021 |
Biosynexus, Inc.
 Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Corporate Officer/Principal | 01-01-2006 |
National Center for Health Statistics
 National Center for Health Statistics General GovernmentGovernment Provides public health statistics | Corporate Officer/Principal | - |
Opleiding van Helen Thackray
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
29
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
BioCryst Pharmaceuticals, Inc.
 BioCryst Pharmaceuticals, Inc. BiotechnologyHealth Technology Designs and develops oral small-molecule & injectable protein therapeutics | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biosynexus, Inc.
Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
GlycoMimetics, Inc.
GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Health Technology |
Holy Cross Hospital (Maryland) | Health Services |
National Center for Health Statistics
National Center for Health Statistics General GovernmentGovernment Provides public health statistics | Government |
Gw School of Medicine & Health Sciences
Gw School of Medicine & Health Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
